Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure-Reference-Cited by-同舟云学术

Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure

Published:2021-03 Issue:3 Volume:39 Page:195.e7-195.e13
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Hurle Rodolfo,Contieri Roberto,Casale Paolo,Morenghi Emanuela,Saita Alberto,Buffi Nicolòmaria,Lughezzani Giovanni,Colombo Piergiuseppe,Frego Nicola,Fasulo Vittorio,Paciotti Marco,Guazzoni Giorgio,Lazzeri Massimo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

3. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what;Peyton;World J Urol,2019

4. Emerging immunotherapy options for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer;Meng;J Urol,2019

5. The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data;Perera;S. BJU Int.,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-22

2. Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review;Cancers;2024-05-11

3. Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine;International Journal of Molecular Sciences;2024-04-29

4. Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study;BMC Urology;2024-01-31

5. Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea;Investigative and Clinical Urology;2024